Clinical Trial Update: Safety and Tolerability of Repeated Subcutaneous Injections of CAD 106 in Mild Alzheimer's Patients [Phase 2]

View source ↗

Summary

Phase 2 trial update assessing safety and tolerability of repeated subcutaneous injections of CAD 106 in patients with mild Alzheimer's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• CAD 106

Snippet

Sponsor: Novartis | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED